The threat of vancomycin resistance
- PMID: 10348061
- DOI: 10.1016/s0002-9343(98)00354-4
The threat of vancomycin resistance
Abstract
Vancomycin, produced in 1958, an essential antibiotic in the modern age, often is reserved for use in patients who are gravely ill or for infections caused by organisms resistant to penicillin, cephalosporin, or other antibiotics. Bacterial resistance to vancomycin has caused great concern among many healthcare professionals. First reported in 1986 in Europe and in 1988 in the United States, vancomycin-resistant enterococci (VRE) have become a major cause of nosocomial infections. During this time, scattered reports of clinical infections caused by vancomycin-resistant coagulase-negative staphylococci also were reported. Recently, enterococci that require vancomycin in media for growth, vancomycin-dependent enterococci (VDE), have been reported to cause clinically significant infections. Vancomycin or other glycopeptide intermediately resistant Staphylococcus aureus (VISA/GISA) also has emerged. The mechanisms of resistance to vancomycin for VRE, and probably for VISA/GISA, relate to the acquired ability of these organisms to circumvent the vancomycin-mediated disruption of bacterial cell wall synthesis. Risk factors that lead to VRE colonization or infection include prior antibiotic therapy, prolonged hospitalization, hospitalization in an intensive care unit, concomitant serious medical and surgical illnesses, exposure to equipment contaminated with VRE, and exposure to patients with VRE. Patients colonized or infected with VRE, healthcare workers with contaminated hands, and environmental surfaces in healthcare facilities are major reservoirs of VRE. Risk factors for VDE and VISA/GISA are less well understood, although both organisms emerge in patients receiving vancomycin or other glycopeptide antibiotics. Infection and antibiotic control procedures for both organisms, including restriction of vancomycin use, optimization of the antibiotic formulary, education of hospital personnel, early detection and reporting of vancomycin resistance, isolation of colonized patients, and appropriate cleansing of the environment are used to prevent the spread of these organisms in healthcare settings.
Similar articles
-
Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC).MMWR Recomm Rep. 1995 Sep 22;44(RR-12):1-13. MMWR Recomm Rep. 1995. PMID: 7565541
-
Seeking vancomycin resistant Staphylococcus aureus among patients with vancomycin-resistant enterococci.Clin Infect Dis. 1999 Dec;29(6):1566-8. doi: 10.1086/313530. Clin Infect Dis. 1999. PMID: 10585815
-
[Vancomycin resistant enterococci].Rinsho Byori. 1998 Jul;46(7):629-36. Rinsho Byori. 1998. PMID: 9721528 Review. Japanese.
-
The risk of developing a vancomycin-resistant Enterococcus bloodstream infection for colonized patients.Am J Infect Control. 2008 Dec;36(10):S175.e5-8. doi: 10.1016/j.ajic.2008.10.010. Am J Infect Control. 2008. PMID: 19084155
-
Recommendations for preventing the spread of vancomycin resistance.Infect Control Hosp Epidemiol. 1995 Feb;16(2):105-13. doi: 10.1086/647066. Infect Control Hosp Epidemiol. 1995. PMID: 7759811 Review.
Cited by
-
Burden of Antibiotic Resistance at Wolaita Sodo University Comprehensive Specialized Hospital.Biomed Res Int. 2022 Jun 2;2022:7272024. doi: 10.1155/2022/7272024. eCollection 2022. Biomed Res Int. 2022. PMID: 38525432 Free PMC article.
-
Current Insights in the Application of Bone Grafts for Local Antibiotic Delivery in Bone Reconstruction Surgery.J Bone Jt Infect. 2019 Oct 15;4(5):245-253. doi: 10.7150/jbji.38373. eCollection 2019. J Bone Jt Infect. 2019. PMID: 31700774 Free PMC article. Review.
-
Eradication of Vancomycin-Resistant Enterococci by Combining Phage and Vancomycin.Viruses. 2019 Oct 16;11(10):954. doi: 10.3390/v11100954. Viruses. 2019. PMID: 31623253 Free PMC article.
-
Reassessing the role of Staphylococcus aureus clumping factor and fibronectin-binding protein by expression in Lactococcus lactis.Infect Immun. 2001 Oct;69(10):6296-302. doi: 10.1128/IAI.69.10.6296-6302.2001. Infect Immun. 2001. PMID: 11553573 Free PMC article.
-
Mannopeptimycins, new cyclic glycopeptide antibiotics produced by Streptomyces hygroscopicus LL-AC98: antibacterial and mechanistic activities.Antimicrob Agents Chemother. 2003 Jan;47(1):62-9. doi: 10.1128/AAC.47.1.62-69.2003. Antimicrob Agents Chemother. 2003. PMID: 12499170 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous